{"database":"ecrin-mdr-crc","file_versions":[],"scores":null,"additional":{"omics_type":["Clinical"],"study_start_year":["2007"],"condition":["Colorectal Cancer","Colonic Neoplasms"],"disease":["Colorectal Cancer","Colonic Neoplasms"],"study_type":["Interventional"],"full_dataset_link":["https://newmdr.ecrin.org/Study/2042187"],"location":["Russia"],"study_start_month":["7"],"keyword":["Capecitabine"],"repository":["ECRIN MDR"],"study_status":["Completed"],"additional_accession":[]},"is_claimable":false,"name":"A Study of Xeloda (Capecitabine) as Adjuvant Monotherapy in Patients With Colon Cancer.","description":"This single arm study will evaluate the safety profile of Xeloda as monotherapy for adjuvant treatment of colon cancer. All patients will receive Xeloda 1250mg/m2 p.o. twice daily as intermittent treatment (3 week cycles consisting of 2 weeks of treatment followed by 1 week without treatment). The anticipated time on study treatment is 3-12 months, and the target sample size is 500+ individuals.","dates":{"creation":"2007-07-15"},"accession":"2042187","cross_references":{"ClinicalTrials___gov":["NCT00502671"]}}